Organogenesis exceeded Q1 FY 2024 revenue expectations and reported better-than-expected EPS.
Organogenesis (ORGO) reported better-than-expected Q1 earnings for FY 2024, with EPS of -$0.02 versus the consensus estimate of -$0.03. The regenerative medicine company exceeded revenue expectations at $109.98M. Cantor Fitzgerald maintained an "overweight" rating and raised its price target to $5.00. Organogenesis focuses on advanced wound care, surgical, and sports medicine markets in the US.
May 10, 2024
5 Articles